8th International Conference on Pediatric Renal Tumor Biology
Presented by The Pablove Foundation and Children’s National Medical Center

Accreditation
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of The George Washington University School of Medicine and Health Sciences and Children’s National Medical Center. The George Washington University School of Medicine and Health Sciences is accredited by the ACCME to provide continuing medical education for physicians

Physician CME Credit
The George Washington University School of Medicine and Health Sciences designates this live activity for a maximum of 24 AMA Physician Recognition Award Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Evaluation and Claiming Credit/ Attendance
At the close of the event, participants will be e-mailed a link to the evaluation. Upon completing the evaluation, participants will be able to complete a credit claim form and print/save a certificate of completion or attendance.

Learning Objectives
1. To recognize new developments in the biology of Wilms tumor, pediatric renal cell carcinoma, and malignant rhabdoid tumor
2. To recognize genetic predisposition syndromes that are associated with pediatric renal tumors
3. To identify novel prognostic biomarkers for Wilms tumor
4. To recognize novel molecular targets for pediatric renal tumors, potential drugs for those targets, and clinical trials available to patients.
5. To discuss the concerns of patients and families affected by pediatric renal tumors to try to improve family-centered care.

Disclosures
GW relies upon its faculty to provide information in a manner that is objective and free from commercial bias. All instructors are required to disclose any relevant financial relationships related to the context of their participation. Their disclosure statements will be available for inspection. Each faculty member also will disclose discussions of unlabeled or investigative use of any commercial product..


Back to top

Speakers
• Nicholas Hastie, CBE, FRS, FRSE
Director, MRC Human Genetics Unit and Director
Institute of Genetics and Molecular Medicine, University of Edinburgh
Wt1 and mesenchyme regulation in Wilms tumor, development and tissue homeostasis

• Jeffrey Toretsky, MD
Georgetown Lombardi Cancer Center
Targeting chromosomal translocation fusion proteins with small molecules

• Michael Atkins, MD
Deputy Director
Georgetown Lombardi Cancer Center
Current and future treatment options for adult RCC: Lessons Learned

• D. Ashley Hill, MD
Chief, Division of Pathology, Children’s National Medical Center
DICER1 mutations and risk for tumors of the kidney

• Malcolm Smith, MD, PhD
Associate Branch Chief
Pediatric Oncology, Cancer Therapy Evaluation Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute (NCI)
Preclinical testing for renal tumors – Lessons from the Pediatric Preclinical Testing Program (PPTP)

• Marston Linehan, MD
Chief of the Urologic Oncology Branch, National Cancer Institute
The genetic basis of kidney cancer: A metabolic disease

---

Program Committee

• Jeffrey Dome, MD, PhD, Children’s National Medical Center, Washington DC, USA
• James Geller, MD, Cincinnati Children’s Medical Center, Cincinnati, USA
• Norbert Graf, MD, University Hospital Homburg, Homburg, Germany
• Vicki Huff, PhD, MD, Anderson Cancer Center, Houston, USA
• Kathy Pritchard-Jones, MBBS, University College London Institute for Child Heath, London, UK

Back to top

Authors to be available at posters on May 9 and May 10 for the morning coffee breaks
• Cajaiba MM et al.: Revisiting the morphological spectrum of pediatric cystic nephromas: the COG experience
• Doros, L et al.: Somatic DICER1 mutations in sporadic cases of cystic nephroma
• Wu MK et al.: Biallelic DICER1 mutations occur in Wilms tumors
• Vokuhl, C: 1q gain in Wilms tumors treated in the SIOP2001/GPOH trial
• Pritchard-Jones K et al.: Copy number analysis of 1q gain in Wilms tumor by multiplex ligation-dependent probe amplification
• Dainese L et al.: 1p and 16q allelic loss in Wilms tumors (Nephroblastoma) in the SFCE/SIOP 2001 Nephroblastoma trial – Are they correlated with pathology
• Romao et al.: Can preoperative identification of constitutional molecular signatures for multifocality impact surgical treatment for Wilms tumor?
• Venkatramani et al.: Treatment of multiply relapsed Wilms Tumor with vincristine, irinotecan, temozolomide, and bevacizumab

Back to top